Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -
MK-5684-01A
Phase 2 small_molecule active
Quick answer
Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , - for Metastatic castration resistant prostate cancer (mCRPC) is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Metastatic castration resistant prostate cancer (mCRPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active